7/5/2024 15:28, SHL
German healthcare technology company Siemens Healthineers published results for the 2Q of fiscal year 2024.
Results for 2Q
Comparable sales grew by 3% compared to 2Q 2023. Excluding the effects of sales from antigen tests for Covid-19, year-on-year growth would have been 11.7%.
Segment sales imaging techniques increased by 1.4% year-on-year to EUR 2.96 billion. Analysts had expected a result of EUR 3.03 billion. Advanced therapies yielded 5.6% more year-on-year to EUR 526 million, while the average analyst estimate was EUR 516.6 million. Segment sales diagnostics increased by 2.1% year-on-year to EUR 1.1 billion. Analysts had expected EUR 1.09 billion. Oncology systems segment Variant year-on-year sales fell by 2.6% to EUR 910 million, falling short of analysts’ expectations of EUR 940 million.
Annual outlook
The company confirmed the existing projections. Comparable sales growth should be in the range of 4.5% to 6.5% against the analyst consensus of 5.49%. Adjusted earnings per share should range between EUR 2.1 and EUR 2.3.
Within the diagnostics segment, it is now projecting an adjusted EBIT margin of between 4% and 6%, the previous outlook was 2.5% to 4.5%.
Shares of Siemens Healthineers
| Siemens Healthineers AG (SHL) -3.5% to €50.62 | |||
|---|---|---|---|
| Pointer | Pointer | ||
| Capitalization (billion EUR) | 57.1 | P/E | 30.5 |
| Development for this year (%) | -3.8 | Expected P/E | 23.0 |
| 52 week minimum (EUR) | 44.4 | Avg. target price (EUR) | 60.2 |
| 52 week high (EUR) | 58.1 | Dividend yield (%) | 1.9 |
Source: Siemens Healthcare, Bloomberg
Marek Chudoba, Fio banka, as
Tags: Siemens Healthineers failed meet analysts estimates imaging technology segment
